Related Experiment Video

Updated: Dec 30, 2025

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
09:03

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

618

Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and

B Wang1, F Wang2, A Ding3

  • 1Ward 3, Department of Hepatology, Jinan Infectious Disease Hospital Affiliated to Shandong University, Jinan, 250021, People's Republic of China.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|January 23, 2020
PubMed
Abstract

Insights

Regorafenib and ginsenoside synergistically inhibit HepG2 liver cancer cell growth. This combination therapy significantly reduces survivin mRNA expression, offering a promising approach for liver cancer treatment.

Area of Science:

  • Hepatocellular Carcinoma Research
  • Pharmacology
  • Molecular Biology

Background:

  • Investigating novel therapeutic strategies for liver cancer.
  • Evaluating the combined effects of regorafenib and ginsenoside.

Purpose of the Study:

  • To assess the inhibitory effects of regorafenib and ginsenoside, alone and in combination, on HepG2 liver cancer cell growth.
  • To explore the molecular mechanisms underlying the combined therapy's efficacy.

Main Methods:

  • HepG2 cells were treated with varying concentrations of regorafenib and ginsenoside, individually and combined.
  • Assessed cell proliferation, survivin mRNA expression via RT-qPCR, and caspase-3 activity.

Main Results:

  • Both single-agent therapies and the combination demonstrated significant inhibition of HepG2 cell growth.
  • The combination therapy exhibited a synergistic inhibitory effect, concentration- and time-dependent.
  • Combined treatment markedly reduced survivin mRNA levels compared to single-agent treatments.

Conclusions:

  • Regorafenib and ginsenoside exhibit synergistic anti-cancer activity against HepG2 cells.
  • The combination therapy shows potential for clinical application in liver cancer treatment.
  • Reduced survivin mRNA expression is a key mechanism in the synergistic effect.
Keywords:
ApoptosisGinsenosideHepG2 cellsLiver cancer cellsRegorafenib

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.5K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.1K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K